What the study reports
Researchers report that CLN8, a protein altered by some mutations causing Batten disease, has a specific role in making a lysosomal lipid called bis(monoacylglycero)phosphate (BMP). The work was published in Nature and used cell experiments, purified protein assays, structural studies, mice and zebrafish models.
Batten disease—also called neuronal ceroid lipofuscinosis—includes inherited lysosomal storage disorders caused by changes in different CLN genes. The paper describes BMP as a lipid found in late endosomes and lysosomes, cellular compartments involved in breaking down and processing material. The authors note that reduced lysosomal function and buildup of lipids and proteins are central features of these disorders.
A newly defined step in BMP production
The researchers found that CLN8 acts as an acyltransferase, an enzyme that transfers a fatty-acid-containing chemical group. More specifically, their experiments indicate that CLN8 converts a molecule called S,S-glycerophosphoglycerol into S,S-lysophosphatidylglycerol (S,S-LPG).
This result helps place CLN8 in a proposed BMP-production pathway. According to the study, S,S-LPG is then used by another Batten disease-associated protein, CLN5, to make S,S-BMP. The authors emphasize the importance of the molecule’s stereochemistry—the three-dimensional arrangement of its components. In laboratory assays with purified CLN8, the enzyme preferentially acted on the S,S form of its substrate.
The team also used cryo-electron microscopy to examine CLN8’s structure. These images identified features of the enzyme’s active site and were reported to support a two-stage, or “ping-pong,” acyl-transfer mechanism.
Evidence from disease-associated variants and models
The researchers report that Batten disease-associated CLN8 mutations reduced enzymatic activity in their experiments. In mice, these changes were associated with loss of BMP production. Together, these findings connect disease-associated CLN8 changes with disruption of a defined biochemical step, rather than only showing that CLN8 is broadly necessary for normal BMP levels.
The paper also tested whether supplying S,S-LPG from outside cells could bypass the missing CLN8 step. The S,S form restored BMP synthesis in CLN8-deficient cells and mice in the reported experiments. The alternative R,S stereoisomer did not do so. In zebrafish carrying a cln8 mutation, the authors reported improvement in neurological features after S,S-LPG treatment.
Why this may matter
For the Batten disease community, the study offers a more detailed explanation of how one CLN8-related form of disease may affect lysosomal lipid biology. It also identifies a potential research direction based on replacing a BMP precursor rather than directly changing the CLN8 gene.
However, the reported precursor-supplementation results are preclinical. The publisher text describes work in cells, mice and zebrafish, not studies in people. It does not provide evidence that S,S-LPG is safe, effective or available as a treatment for people with CLN8-related Batten disease. Further research would be needed to assess dosing, delivery, durability, safety and whether findings in laboratory models translate to human disease.